AstraZeneca’s COPD Breakthrough Drug | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded08 Sep 2026

Publisherfeeds.acast.com ↗

Handlerec:20296433

Show notes

AstraZeneca’s new COPD drug, tozorakimab, is poised to revolutionize treatment—showing dramatic reductions in flare-ups across diverse patient groups, including non-smokers. With FDA approval expected early 2027 and projected peak sales of $5 billion, this inflammation-targeting therapy could reshape how millions manage a leading cause of death, offering hope where current treatments fall short. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fd09a129c1a9cb0c

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.